Abstract IA013: Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy

作者
Neeha Zaidi,Amanda L. Huff,Emily Marcisak-Davis,Saurav Daniel Haldar,Thatcher Ross Heumann,Max Konig,Brian J. Mog,Janelle Marie Montagne,Gabriella Longway,Lalitya Andaloori,Melissa R. Lyman,Ludmila Danilova,Julie M. Nauroth,Luciane Tsukamoto Kagohara,Elana Judith Fertig,Nilo Azad,Elizabeth M. Jaffee
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (22_Supplement): IA013-IA013 被引量:5
标识
DOI:10.1158/1538-7445.panca22-ia013
摘要

Abstract The evolution of pancreatic ductal adenocarcinoma (PDAC) from tumor initiation to metastases requires years to decades, providing a window of opportunity for the prevention of premalignant progression. One of the first genetic mutations to occur early in development is in KRAS, an oncogene that is expressed by over 90% of PDACs. KRAS mutations (mKRAS) are attractive targets as they are recurrent hot–spot drivers that are expressed by, and drive the growth of all PDAC cells. Preclinical data provide compelling evidence that targeting mKRAS proteins using a Listeria-based vaccination approach in KPC mouse model results in prevention of progression from precursor lesions to PDAC. Based on these data, we hypothesize that targeting mKRAS in combination with bypassing early immune–suppressive signals will slow or even halt the progression of precursor lesions to PDA in subjects who are at high–risk. We have thus developed a clinical–grade long peptide vaccine targeting the six most common mKRAS proteins (G12V, G12R, G12A, G12C, G12D, and G13D) in PDAC patients. To establish initial safety and immunogenicity, our KRAS vaccine has been tested in 11 patients thus far in a Phase 1 clinical trial (NCT04117087) in combination with checkpoint blockade in patients who have undergone surgery and peri–operative chemotherapy and remained disease–free on imaging. Longitudinal immune data demonstrates an induction of activated and poly-functional mKRAS-specific CD4+ and CD8+ T cells, as well as effector and central memory T cells post–vaccination. In parallel, we performed paired single-cell RNA and TCR sequencing in PBMCs from a patient to obtain greater resolution of the vaccine–induced cytotoxic anti–tumor T cells. We captured 66,869 immune cells across three timepoints for analysis. Notably, we similarly observed an expansion of central memory CD4+ and CD8+ T cells post–vaccination. Using a novel computational algorithm (developed in collaboration with Dr. Elana Fertig’s lab) that takes into account physiochemical similarity of known mKRAS TCRs, we used our single–cell dataset to identify mKRAS-reactive TCRs` in the periphery that were functionally validated in vitro using CRISPR-Cas12a-based genome editing of human T cells. Overall, these studies suggest the induction of de novo, high quality mutant KRAS–specific T cells in the peripheral blood post–vaccination. Based on these immune data, we are enrolling onto a second clinical trial testing our mKRAS peptide vaccine in patients who are at high risk for developing PDAC (NCT05013216). These high-risk groups include those with strong family histories of PDAC or known pathogenic germline variants with a lifetime risk of up to 10% of developing PDA. Our preliminary data in our first three vaccinated patients shows an induction of mKRAS–specific T cell responses in the peripheral blood. Further studies characterizing the T cell response will lay the foundation for peripheral T cell–based biomarkers that could be used to predict response in a prevention setting. Citation Format: Neeha Zaidi, Amanda Huff, Emily Marcisak-Davis, Daniel Haldar, Thatcher Heumann, Max Konig, Brian Mog, Janelle Montagne, Gabriella Longway, Lalitya Andaloori, Melissa Lyman, Ludmila Danilova, Julie Nauroth, Luciane Kagohara, Elana Fertig, Nilo Azad, Elizabeth Jaffee. Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr IA013.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被某叶采纳,获得20
刚刚
刚刚
刚刚
1秒前
1秒前
苗条书桃完成签到,获得积分10
1秒前
2秒前
2秒前
无极微光的应助被仁爱思真采纳,获得20
2秒前
复杂的忆寒完成签到,获得积分20
3秒前
3秒前
奋斗完成签到 ,获得积分10
3秒前
研友_VZG7GZ的应助被吴少华采纳,获得10
3秒前
科研通AI2S的应助被袁钢采纳,获得10
3秒前
4秒前
挚友发布了新的文献求助10
4秒前
爱听歌飞丹的应助被小龙GG采纳,获得10
4秒前
4秒前
5秒前
wyq关闭了wyq的文献求助
5秒前
NULI完成签到,获得积分10
5秒前
5秒前
萱草完成签到 ,获得积分10
5秒前
6秒前
6秒前
想要礼物的艾斯米拉达完成签到,获得积分10
6秒前
DW的应助被科研通管家采纳,获得10
6秒前
情怀的应助被科研通管家采纳,获得10
6秒前
小蘑菇的应助被科研通管家采纳,获得10
6秒前
李爱国的应助被zgxj采纳,获得10
6秒前
Jasper的应助被科研通管家采纳,获得30
6秒前
33发布了新的文献求助10
6秒前
wanci的应助被YZzzJ采纳,获得10
7秒前
DW的应助被科研通管家采纳,获得10
7秒前
星辰大海的应助被科研通管家采纳,获得10
7秒前
Akim的应助被科研通管家采纳,获得10
7秒前
7秒前
香蕉觅云的应助被ZJH采纳,获得10
7秒前
西西歪发布了新的文献求助100
7秒前
顺顺利利的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124